Medication info
Eurosatin Tablets 10 mg (Rosuvastatin Calcium)

Eurosatin Tablets 10 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Yu Yu Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets/box [14 tablets/Alu-AluX2]
Approval status
Active

MFDS item code 201001000 · Approved 2010.01.28 · Insurance code 644501730

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg per day. 3. Older adults : No dosage adjustment is necessary. 4. Patients with renal impairment : No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in the pediatric population.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Yu Yu Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • cardiovascular disease
  • coronary heart disease
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
View approved original text

This medication is used as an adjunct when dietary changes and exercise alone are insufficient to control primary hypercholesterolemia, particularly in patients with heterozygous familial hypercholesterolemia and mixed hyperlipidemia. It is also used as an adjunct in patients with homozygous familial hypercholesterolemia along with other lipid-lowering therapies, helping to lower total cholesterol and LDL cholesterol levels, thereby slowing the progression of atherosclerosis. It is effective in children aged 10 to 17 years with heterozygous familial hypercholesterolemia when dietary control is inadequate. It is also used as an adjunct in patients with primary dysbetalipoproteinemia. Moreover, it is useful in reducing the risk of stroke, myocardial infarction, and percutaneous coronary intervention in high-risk adult patients with elevated high-sensitivity C-reactive protein and additional cardiovascular risk factors. In summary, this drug is used to reduce the risk associated with various types of hypercholesterolemia and related cardiovascular diseases, improving blood lipid levels and protecting cardiovascular health.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg per day. 3. Older adults : No dosage adjustment is necessary. 4. Patients with renal impairment : No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in the pediatric population.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used by patients with known allergies to any of the components. Patients with active liver disease or severe liver dysfunction should not take this medication. It should also not be administered to patients with muscle disease or severe kidney dysfunction. Pregnant or breastfeeding women and women of childbearing potential should consult a physician before taking this medication and use appropriate contraception. This medication can affect muscle tissue, so extra caution is needed for patients at high risk of muscle pain or myopathy, and high doses are contraindicated. It contains lactose; therefore, patients with lactose intolerance or related genetic disorders should not take it. Patients with a history of liver function abnormalities or those consuming alcohol heavily should undergo regular liver function tests, and treatment should be undertaken after addressing hypothyroidism or other conditions. If symptoms such as muscle pain, weakness, or cramps occur, patients should notify their doctor immediately and may need to discontinue the medication. This medication may increase blood levels when taken with certain medications, raising the risk of muscle-related adverse effects, so patients must inform their physician about concomitant medications. Reported side effects from clinical trials and post-marketing include headache, dizziness, gastrointestinal disturbance, skin rash, and muscle pain; in severe cases, myopathy or liver function abnormalities may occur. It should be avoided during pregnancy due to risks to the fetus and is discouraged while breastfeeding as it may pass into breast milk. There is no specific antidote for overdose, and treatment should be symptomatic while monitoring liver function and muscle enzyme levels. Caution is necessary while driving or operating machinery due to possible dizziness. This medication may show higher systemic exposure in Asians, so dose adjustments may be necessary.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegic weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, elevated ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, dysesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air or moisture ingress, ideally at a cool temperature below 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets/box [14 tablets/Alu-AluX2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.